Startups

Modulo Bio

San Diego, California, United States

Modulo Bio, Inc. is a Delaware biotechnology corporation founded in2021, based in San Diego. It develops neuroimmune therapies for neurological diseases by studying and reprogramming microglia, the brain’s resident immune cells. Its Modulo Neuroimmune Platform combines patient-derived stem-cell models of microglia, neurons and astrocytes with CRISPR, single-cell multiomics, software, automation and machine learning. The company compares biological signals across complementary models to identify targets, biomarkers and drug candidates for ALS, frontotemporal dementia and other neurodegenerative conditions. Its published current team has eleven named members, including co-founders Mike (Michael) Horowitz, Scott (Alexander Scott) Patterson and Justin Ichida. Joseph (Joe) Wagner was announced as Chief Development Officer inJune2025. Nicholas Saccomano and Edmund Harrigan were announced as board directors inJuly2025; Saccomano already appears in a November2024 SEC director disclosure, so that announcement does not establish a new first appointment date. The legal issuer’s CIK is1867562. It is distinct from the unrelated cybersecurity company Modulo at modulo.com. The June1,2023 issuer launch announcement reports USD8M in funding from seven institutional investors; the retained financing record is preserved without inferring individual allocations or adding earlier securities offerings again. The company announced receipt of a USD500K ALS Association research grant onFebruary7,2025 and a USD4.8M ADDF strategic equity investment onMarch19,2025. Those announcements do not establish exact payment dates. Its November2024 FormD reports USD5,845,788 sold in a USD7.5M equity offering; investor identities and overlap with the later announced ADDF investment are not established, so it is not counted as additional cash. Joining Lilly Gateway Labs provides facilities and expertise, and does not by itself establish a Lilly equity investment.

Founded 2021

Team

Alda Leu DennisBoard Director (reported November 2024)

Apuleyo YanezResearch Associate

Brent WilkinsonScientist

Edmund HarriganBoard Director

Hannah ZhengSenior Research Associate

Joe WagnerChief Development Officer

Justin IchidaCo-Founder

Karen SachsDirector of Computational Biology

Mike HorowitzCEO & Co-Founder

Nicholas SaccomanoBoard Director

Nina DraegerSenior Scientist

Ryan LimDirector of Biology

Scott PattersonCTO & Co-Founder

Steven SchaffertPrincipal Data Scientist

Investments

$847K2026-09-19	National Institutes of Health
$1M2026-02-25	National Institutes of Health
$4M2025-03-19	Alzheimer's Drug Discovery Foundation
$500K2025-02-07	ALS Association
$8M2023-06-01	Cantos, Initialized Capital, Bioverge Inc, Hawktail, Builders VC, Spacecadet Ventures, Refactor Capital
$—Unknown date	LifeSpan Vision Ventures

team@apexlogos.ai16 hours ago
Additional primary federal grant audit: official NIHReporter API https://api.reporter.nih.gov/v2/projects/search selected exact MODULO BIO FY2026. NIMH1R61MH143793-01 noticeFebruary25,2026 awarded1,479,470USD budgetMarch2026–February2028; NINDS1R44NS143633-01A1 noticeSeptember19,2026 awarded847,695USD budgetSeptember2026–August2027, not fullprojectfuturefunding throughAugust2028. Both awards representedonceunderfullNationalInstitutesOfHealth10683 with exactadministeringinstitute qualifications; no PIpersonalcheck. Awarddates are not proved payment dates. DoD FY2025 ALS TherapeuticDevelopment recommendedapplications page https://cdmrp.health.mil/alsrp/awards/25tdaawards explicitlydisclaims fundingguarantee; Modulo/RyanLim recommendation not counted as actualaward orcash. Missing2023fullbuyers Bioverge/Builders/Refactor/Spacecadet/Hawktail remainfullprofilecallbackqueue; no thinbuyers fabricated.
team@apexlogos.ai16 hours ago
Funding/identity audit: unrelated cybersecurity Modulo/modulo.com retained. Earlier incorrect alias round23827/IP53561 already removed by prior primary-source audit; current correct8M round23828 and protectedCantos4179IP53562 remain. 2023source reports8M launch funding, not investor-specific tickets; earlier2021offering is not added again without proving exclusion from8M. November20,2024 SEC https://www.sec.gov/Archives/edgar/data/1867562/000186756224000001/xslFormDX01/primary_doc.xml reports equity5,845,788 sold against7.5M target; unnamed subscribers/overlap with ADDF4.8M announcement unknown, so no additive financedcash recorded. SEC2024 names MichaelHorowitz, AlexanderScottPatterson, AldaLeuDennis, NicholasSaccomano directors; historical disclosure is not assumed a complete current2026board. Current staff11 and issuer2025board additions separately qualified. Lilly Gateway Labs is infrastructure/scientific support, no inferred equitycheck. Future milestones/clinicalefficacy are not funding or proven outcomes.
team@apexlogos.ai2 days ago
Current11publishedteam and microglia neuroimmune platform verified at https://www.modulo.bio/about and https://www.modulo.bio/platform. LifeSpan currentholding https://www.lifespanvisionventures.com/portfolio hasundiscloseddateamountvehicle. AuthenticcurrentMODULOwordmark saved. March2025ADDF4.8m andFeb2025ALS500k requireinstrumentverification beforeequity. Reconciled duplicate financing: issuer announcement https://markets.financialcontent.com/stocks/article/bizwire-2023-6-1-modulo-bio-launches-to-map-the-neuroimmune-system-and-develop-treatments-for-neurodegenerative-diseases-starting-with-als-and-ftd confirms June1,2023 USD8m financing belongs to Modulo Bio, not Modulo cybersecurity. Correct round23828 and Cantos participation53562 retained with primary evidence. Incorrect duplicate round23827 and participation53561 deleted through Records toolkit after dependency dry-run. Modulo and Modulo Bio remain separate companies.